Original Review ArticleMolecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer DiseaseGandy, Sam MD, PhD; Martins, Ralph N. PhD; Buxbaum, Joseph PhDAuthor Information From the Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, Pennsylvania (Dr Gandy); Edith Cowan University, Perth, WA, Australia (Dr Martins); and Laboratory of Molecular Neuropsychiatry, Departments of Neurobiology and Psychiatry, Mt. Sinai School of Medicine, New York, New York (Dr Buxbaum). Received for publication June 23, 2003; accepted September 25, 2003. Supported by the USPHS, the New York State Office of Mental Health, the Research Foundation for Mental Hygiene, and the Farber Family Foundation. Dr. Gandy has received extramural support from: 1) the Women's Health Research Institute of Wyeth-Ayerst Research, a division of American Home Products Corporation; 2) Pfizer/Eisai; and 3) Andrx; and he has received consulting fees from 1) Parke-Davis Pharmaceuticals (now Pfizer Ann Arbor), 2) F. Hoffman La Roche (Basel), and 3) the Pharmacia Corporation. Reprints: Sam Gandy, MD, PhD, Farber Institute for Neurosciences, Thomas Jefferson University, 900 Walnut Street, Suite 467, Philadelphia, PA 19107 (e-mail: firstname.lastname@example.org). Alzheimer Disease & Associated Disorders: October-December 2003 - Volume 17 - Issue 4 - p 259-266 Buy © 2003 Lippincott Williams & Wilkins, Inc.